U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news
More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | Jardiance | Metformin | Research